Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid

被引:41
作者
Labrie, F [1 ]
Luu-The, V [1 ]
Calvo, E [1 ]
Martel, C [1 ]
Cloutier, J [1 ]
Gauthier, S [1 ]
Belleau, P [1 ]
Morissette, J [1 ]
Lévesque, MH [1 ]
Labrie, C [1 ]
机构
[1] Univ Laval, Med Res Ctr, Mol Endocrinol & Oncol Lab, Quebec City, PQ G1V 4G2, Canada
关键词
D O I
10.1677/joe.1.05997
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Tetrahydrogestrinone (THG) is a recently identified compound having the greatest impact in the world of sports. In order to obtain a highly accurate and sensitive assessment of the potential anabolic/androgenic activity of THG, we have used microarrays to identify its effect on the expression of practically all the 30 000 genes in the mouse genome and compared it with the effect of dihydrotestosterone (DHT), the most potent natural androgen. Quite remarkably, we found that 671 of the genes modulated by THG in the mouse muscle levator am are modulated in a similar fashion by DHT, while in the gastrocnemius muscle and prostate, 95 and 939 genes respectively, are modulated in common by the two steroids. On the other hand, THG is more potent than DHT in binding to the androgen receptor, while, under in vivo conditions, THG possesses 20% of the potency of DHT in stimulating prostate, seminal vesicle and levator am muscle weight in the mouse. The present microarray data provide an extremely precise and unquestionable signature of the androgenic /anabolic activity of THG, an approach which should apply to the analysis of the activity of any anabolic steroid.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 31 条
[1]
AZADIANBOULANGE.G, 1973, P 7 WORLD C FERT STE, P129
[2]
DEPRESSED TRANSLATIONAL ACTIVITY IN THE ANDROGEN SENSITIVE LEVATOR ANI MUSCLE OF THE RAT [J].
BOISSONNEAULT, G ;
GAGNON, J ;
HOKIM, MA ;
ROGERS, PA ;
TREMBLAY, RR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 32 (04) :507-513
[3]
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia [J].
Bullinger, L ;
Döhner, K ;
Bair, E ;
Fröhling, S ;
Schlenk, RF ;
Tibshirani, R ;
Döhner, H ;
Pollack, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1605-1616
[5]
Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine [J].
Catlin, DH ;
Ahrens, BD ;
Kucherova, Y .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (13) :1273-1275
[6]
COUTINHO EM, 1989, ACTA OBSTET GYN SCAN, P39
[7]
REGRESSION OF UTERINE LEIOMYOMAS AFTER TREATMENT WITH GESTRINONE, AN ANTIESTROGEN, ANTIPROGESTERONE [J].
COUTINHO, EM ;
BOULANGER, GA ;
GONCALVES, MT .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (04) :761-767
[8]
Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis [J].
Dawood, MY ;
Obasiolu, CW ;
Ramos, J ;
KhanDawood, FS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (02) :387-394
[9]
A benefit-risk assessment of medical treatment for uterine leiomyomas [J].
De Leo, V ;
Morgante, G ;
La Marca, A ;
Musacchio, MC ;
Sorace, M ;
Cavicchioli, C ;
Petraglia, F .
DRUG SAFETY, 2002, 25 (11) :759-779
[10]
Tetrahydrogestrinone is a potent androgen and progestin [J].
Death, AK ;
McGrath, KCY ;
Kazlauskas, R ;
Handelsman, DJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2498-2500